Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia

NCT01002495 is registered in ClinicalTrials.gov with Helixmith Co., Ltd. as lead sponsor.

NCT NCT01002495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01002495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia
Lead sponsor
Helixmith Co., Ltd.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
March 31, 2015
Completion date
January 31, 2016
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial ischemia